MedTrace Logo

Continuous Glucose Monitoring for Various Degrees of Glucose Intolerance

NCT05491954 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2022-09-21

No results posted yet for this study

Summary

Diabetes mellitus affects roughly 8% of pregnancies but is associated with significant perinatal and maternal morbidity, with 6% of pregnancies affected by gestational diabetes mellitus (GDM). Best practice guidelines recommend universal screening for gestational diabetes mellitus between 24-28 weeks of pregnancy in all women who do not have a diagnosis of pre-gestational diabetes mellitus. Among high-risk populations, performing an early diabetes screen is suggested at the initiation of prenatal care to evaluate for pre-gestational diabetes mellitus. Prior studies have demonstrated a difference in perinatal outcomes by comparing women with negative screening tests to those who fail a screen but pass a diagnostic test and those who are ultimately diagnosed with GDM. The investigators aim to use continuous glucose monitoring systems to study glycemic control in the early third trimester to further elucidate the differences between pregnant women with euglycemia, glucose intolerance, and GDM.

Conditions

  • Diabetes, Gestational

Interventions

DEVICE

Dexcom G6

Continuous glucose monitoring

Sponsors & Collaborators

  • Ohio State University

    lead OTHER

Principal Investigators

  • Elizabeth Buschur, MD · tOSU Medical Center

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-08-31
Completion
2023-08-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05491954 on ClinicalTrials.gov